Literature DB >> 15572722

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.

Brian L Strom1.   

Abstract

Keywords:  Health Care and Public Health

Mesh：

Substances：

Year:  2004        PMID： 15572722     DOI： 10.1001/jama.292.21.2643

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  12 in total

Review 1.  Drug safety and the media.

Authors:  Patrick C Waller; Stephen J W Evans; Keith Beard
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

2.  Private-sector research ethics: marketing or good conflicts management? The 2005 John J. Conley Lecture on Medical Ethics.

Authors:  Rebecca Dresser
Journal:  Theor Med Bioeth       Date:  2006

3.  Risk perception and reasons for noncompliance in pharmacovigilance: a qualitative study conducted in Canada.

Authors:  Vincent Nichols; Isabelle Thériault-Dubé; Julie Touzin; Jean-François Delisle; Denis Lebel; Jean-François Bussières; Benoît Bailey; Johanne Collin
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  Key concepts of clinical trials: a narrative review.

Authors:  Craig A Umscheid; David J Margolis; Craig E Grossman
Journal:  Postgrad Med       Date:  2011-09       Impact factor: 3.840

Review 5.  Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes.

Authors:  Eleanor S Segal; Cecile Valette; Laurence Oster; Luc Bouley; Catarina Edfjall; Peter Herrmann; Massimo Raineri; Mary Kempff; Saundra Beacham; Cinda van Lierop
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Safety monitoring of drugs receiving pediatric marketing exclusivity.

Authors:  P Brian Smith; Daniel K Benjamin; M Dianne Murphy; Rosemary Johann-Liang; Solomon Iyasu; Barbara Gould; Robert M Califf; Jennifer S Li; William Rodriguez
Journal:  Pediatrics       Date:  2008-09       Impact factor: 7.124

7.  Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).

Authors:  Manfred Hauben; Lester Reich; Charles M Gerrits; David Madigan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

8.  Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis.

Authors:  Jay R McDonald; Angelique L Zeringue; Liron Caplan; Prabha Ranganathan; Hong Xian; Thomas E Burroughs; Victoria J Fraser; Fran Cunningham; Seth A Eisen
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

9.  Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process.

Authors:  Margaret T Whitstock; Christopher M Pearce; Stephen C Ridout; Elizabeth J Eckermann
Journal:  BMC Public Health       Date:  2011-05-21       Impact factor: 3.295

10.  Why drug safety should not take a back seat to efficacy.

Authors:  Virginia Barbour; Jocalyn Clark; Susan Jones; Melissa Norton; Paul Simpson; Emma Veitch
Journal:  PLoS Med       Date:  2011-09-27       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.